← 返回

CAR 介导的靶点识别限制 TCR 和 CAR 双受体编辑 T 细胞的 TCR 介导靶点识别

英文原题:CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.

查看英文原题

CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.

PubMed 2025/02/28(内容时间) Mol Ther Q1 · IF 11.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

抗原逃逸可削弱嵌合抗原受体(CAR)或T细胞受体(TCR)工程化T细胞的疗效。靶向多种抗原可有效限制抗原逃逸,而将CAR与TCR介导的靶向相结合可显著拓宽可靶向抗原的范围。

在此,我们探讨了能否通过联合TCR和CAR工程在T细胞上赋予双抗原特异性,以防止多发性骨髓瘤(MM)的抗原逃逸。我们报道了生成经转导表达转基因TCR的CD8 T细胞,该TCR靶向HLA-B 07:02背景下源自转录辅激活因子BOB1的肽,同时表达靶向BCMA的CAR。这些T细胞被称为TRaCR T细胞,能够有效识别对BOB1 TCR或BCMA CAR-T 细胞耐药的靶细胞,说明其具有普遍的双特异性。

然而,在两种抗原均存在时,靶细胞识别优先由CAR介导,从而损害TCR介导的靶细胞识别。重要的是,在异质性MM体内模型中,这导致缺乏BCMA表达的肿瘤细胞获得生存优势。

总之,我们证明了TRaCR T细胞具有普遍的双特异性,但建议在将TRaCR T细胞作为靶向异质性肿瘤策略时需谨慎。

展开英文摘要原文

Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens.

Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM).

We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B 07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition.

Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM.

In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.

论文信息

作者
Wachsmann TLA、Poortvliet T、Meeuwsen MH、Remst DFG、Toes MF、Wouters AK、Hagedoorn RS、Falkenburg JHF
单位
Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands. Electronic address: t.l.a.wachsmann@lumc.nl.Netherlands
期刊
Molecular therapy : the journal of the American Society of Gene Therapy2025 Apr 2
原文标识
PubMed 40022447 · DOI 10.1016/j.ymthe.2025.02.035